Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and chemotherapies; thus, demand is high for safer, more-efficacious drugs. In the first line, FOLFIRINOX and Celgene’s Abraxane with gemcitabine therapy have emerged as alternative treatment strategies, while in the second line, Merrimack’s Onivyde appears to be a gaining traction. These therapies offer only modest survival benefits (overall survival is less than one year). Although current treatment is dominated by chemotherapies, upcoming targeted therapies, including AstraZeneca / Merck’s Lynparza, are expected to be better-tolerated options.

Questions answered:

  • What are the sizes of the U.S., EU5, and Japanese pancreatic cancer and PNET drug-treatable patient populations? How will drug-treatment rates change over our ten-year forecast period?
  • How are patients with pancreatic cancer and PNETs treated in the markets under study? What are interviewed experts’ insights on current treatment options?
  • What clinical needs remain unfulfilled, and which needs will be addressed by the end of our ten-year forecast period?
  • What are the key emerging therapies in development for pancreatic cancer and PNETs? What sales / uptake could these therapies secure in the pancreatic cancer market? What does the early-phase pipeline look like?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Pancreatic Cancer - Key Findings
    • Key Updates
      • December 2019
      • August 2019
      • June 2019
      • December 2017
      • August 2017
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Pancreatic Cancer?
        • What Factors Are Constraining the Market for Pancreatic Cancer?
      • Segment-Specific Trends
        • Resectable (Stage I-IIB)
        • Unresectable (Stage III), First Line
        • Metastatic, First Line
        • Metastatic, Second Line
    • Forecast
      • Market Forecast Assumptions - Pancreatic Cancer (2018-2028) - December 2019
      • Market Forecast Dashboard - Pancreatic Cancer (2018-2028) - December 2019
    • Etiology and Pathophysiology
      • Disease Overview
        • Etiology
        • Disease Pathophysiology
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Pancreatic Cancer
        • Recurrent Incident Cases of Pancreatic Cancer
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
        • Expert Insight
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Mechanism of Action of Key Current Drugs or Drug Classes Used for Pancreatic Cancer
        • Current Treatments Used for Pancreatic Cancer
        • Therapies for Pancreatic Adenocarcinoma
        • Therapies for Pancreatic Neuroendocrine Tumors
      • Medical Practice
        • Pancreatic Cancer: Resectable (Stage I-IIB)
        • Pancreatic Cancer: Unresectable (Stage III) and Metastatic (Stage IV), First-Line
        • Pancreatic Cancer: Metastatic, Second-Line
        • Pancreatic Neuroendocrine Tumors: Resectable (Stage I-II)
        • Pancreatic Neuroendocrine Tumors: Unresectable (Stage III) and Metastatic (Stage IV), First-Line
        • Pancreatic Neuroendocrine Tumors: Metastatic, Second-Line
        • Region-Specific Treatment Practices
    • Unmet Need
      • Current and Future Attainment of Unmet Needs in Pancreatic Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Pancreatic Cancer
        • Alkylating Agents
        • C-KIT Tyrosine Kinase Inhibitors
        • Dendritic Cell Cancer Vaccines
        • Monoclonal Antibodies
        • PARP Inhibitors
        • Platinum Agents
        • Targets of Cancer Cell Metabolism
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Pancreatic Cancer
    • Access & Reimbursement
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Pancreatic Cancer Bibliography

Author(s): Ananya Sadhu, Ph.D

Ananya Sadhu, is an analyst with the oncology team at Decision Resources Group with expertise in multiple oncology indications including pancreatic cancer. Prior to joining Decision Resources Group, Dr. Ananya Sadhu was a postdoctoral fellow at National Centre of Biological Sciences, Bangalore, where she studied the role of chromatin architecture in regulating gene expression in breast cancer. Ananya holds a in Molecular Biology from National Institute of Immunology, New Delhi. She also worked as a Scientific Officer with Arvind Remedies Ltd., a pharmaceutical company, where she coordinated various stages of non-clinical / clinical research activities for drug development of a patented polyherbal formulation.


Related Reports

Pancreatic Cancer | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevale...

View Details

Pancreatic Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key  pancreatic cancer&nb...

View Details